Alterity Therapeutics Ltd ADR (ATHE)

$4.41 +0.01 (0.34%)
Market Cap 39.02M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,100
Avg Vol 46,002
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 21%
Beta 0.80
Analysts Strong Sell
Price Target $11.00

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 tha...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Address:
350 Collins Street, Suite 4 Level 14, Melbourne, Australia
BrokersNY
BrokersNY Jun. 16 at 8:23 AM
$ATHE despite the global events, very good accumulation this week.
0 · Reply
VicTruth17
VicTruth17 Jun. 16 at 1:13 AM
$ATHE PR week… wonder what Doc Stamler have in store for us :)
1 · Reply
VicTruth17
VicTruth17 Jun. 13 at 2:47 PM
$ATHE added fresh batch of 100 shares :) like for 500 today maybe?
0 · Reply
FamilyVacation
FamilyVacation Jun. 13 at 2:14 PM
$ATHE 😕
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 13 at 2:36 AM
$ATHE added 690 shares today, its a lifestyle
0 · Reply
ButcherBillCutting
ButcherBillCutting Jun. 11 at 5:27 PM
$ATHE If you are watching paint dry; Another good sign for drug approvals. Changes via current Gov. are not Stalling this important process Especially for FDA fast tracks, priority Reviews, orphan drugs etc. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
1 · Reply
VicTruth17
VicTruth17 Jun. 11 at 12:38 AM
$ATHE yall welcome for the AH pump 🤣… been adding slots of 50 to feel like a market maker 🤣🤣… as funds clear I don’t want to get caught by a trade halt 👀 Do it Doc Stamler
1 · Reply
FamilyVacation
FamilyVacation Jun. 10 at 6:10 PM
$ATHE anyone know why the sudden drop?
0 · Reply
theaussiebloke
theaussiebloke Jun. 9 at 6:22 AM
$ATHE they be releasing the 202 results this week or early next week priot to the upcoming Bio meeting 17-19th
3 · Reply
FamilyVacation
FamilyVacation Jun. 7 at 12:36 PM
$ATHE did anyone have issues in buying shares yesterday? I had to keep buying in small portions or else it wouldn’t let me. ??
1 · Reply
Latest News on ATHE
Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025, 7:35 AM EDT - 5 weeks ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 5 weeks ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025, 7:35 AM EDT - 6 weeks ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 6 weeks ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 28, 2025, 7:35 AM EDT - 7 weeks ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Apr 10, 2025, 7:35 AM EDT - 2 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 4 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 30, 2025, 7:35 AM EST - 4 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 5 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Jan 9, 2025, 7:25 AM EST - 5 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Dec 4, 2024, 7:35 AM EST - 6 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 19, 2024, 7:25 AM EST - 7 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 12, 2024, 7:35 AM EST - 7 months ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 7 months ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 8 months ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 14, 2024, 7:35 AM EDT - 8 months ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 11, 2024, 7:35 AM EDT - 8 months ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 30, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 11 months ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 11 months ago

Alterity Therapeutics to Present at MST Financial Webinar

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:35 AM EDT - 11 months ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 11 months ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Jan 29, 2024, 7:24 AM EST - 1 year ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 21, 2023, 12:30 AM EST - 1 year ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 4:35 PM EST - 1 year ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Dec 4, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Nov 27, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Nov 16, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Nov 8, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Oct 30, 2023, 7:25 AM EDT - 1 year ago

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Aug 31, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

Aug 23, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

Aug 22, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Aug 15, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Jul 31, 2023, 7:52 AM EDT - 2 years ago

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

Jul 26, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

Jun 21, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

BrokersNY
BrokersNY Jun. 16 at 8:23 AM
$ATHE despite the global events, very good accumulation this week.
0 · Reply
VicTruth17
VicTruth17 Jun. 16 at 1:13 AM
$ATHE PR week… wonder what Doc Stamler have in store for us :)
1 · Reply
VicTruth17
VicTruth17 Jun. 13 at 2:47 PM
$ATHE added fresh batch of 100 shares :) like for 500 today maybe?
0 · Reply
FamilyVacation
FamilyVacation Jun. 13 at 2:14 PM
$ATHE 😕
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 13 at 2:36 AM
$ATHE added 690 shares today, its a lifestyle
0 · Reply
ButcherBillCutting
ButcherBillCutting Jun. 11 at 5:27 PM
$ATHE If you are watching paint dry; Another good sign for drug approvals. Changes via current Gov. are not Stalling this important process Especially for FDA fast tracks, priority Reviews, orphan drugs etc. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
1 · Reply
VicTruth17
VicTruth17 Jun. 11 at 12:38 AM
$ATHE yall welcome for the AH pump 🤣… been adding slots of 50 to feel like a market maker 🤣🤣… as funds clear I don’t want to get caught by a trade halt 👀 Do it Doc Stamler
1 · Reply
FamilyVacation
FamilyVacation Jun. 10 at 6:10 PM
$ATHE anyone know why the sudden drop?
0 · Reply
theaussiebloke
theaussiebloke Jun. 9 at 6:22 AM
$ATHE they be releasing the 202 results this week or early next week priot to the upcoming Bio meeting 17-19th
3 · Reply
FamilyVacation
FamilyVacation Jun. 7 at 12:36 PM
$ATHE did anyone have issues in buying shares yesterday? I had to keep buying in small portions or else it wouldn’t let me. ??
1 · Reply
VicTruth17
VicTruth17 Jun. 6 at 7:25 PM
$ATHE yall ready to end green? Let’s see what MMs :)
0 · Reply
VicTruth17
VicTruth17 Jun. 6 at 1:36 PM
$ATHE I mean….. $70M MC for a $3-5B buyout price? … you know lol
0 · Reply
theaussiebloke
theaussiebloke Jun. 6 at 1:22 PM
$ATHE it would appear pre market now back to reasonable price, i take back previous post.
0 · Reply
FamilyVacation
FamilyVacation Jun. 6 at 1:18 PM
$ATHE from what I am reading on this board the current pride is a good entry??
0 · Reply
theaussiebloke
theaussiebloke Jun. 6 at 10:51 AM
$ATHE 10% drop pre market, big holders (NYBM) driving and playing us small holders like puppets...i hope alterity are super close lipped and punish them in
2 · Reply
tommy_john
tommy_john Jun. 5 at 10:10 AM
$ATHE LOVE LOVE LOVE the chart! Also love that this is still hasn’t really been found. Might say “I wish I was all in” a few months from now.
0 · Reply
VicTruth17
VicTruth17 Jun. 5 at 12:01 AM
$ATHE SPECIAL thanks to the MM who fed me the shares today… I will keep buying 🤪 because this will boom! For sanity purposes, I needed to re-listen to Doctor Stamler yell “Accelerated Approval” indirectly but for real… FDA will play nice but any day now :) Open shot with no competition at all $1.3B market with more potential with other PD indications? We’re trading at $8 pre dilution but doesn’t matter… the massive gains are upon us 🥰 https://youtu.be/LHHcJiIhA0A?si=sqf3HIEWm3H8QU6H
2 · Reply
VicTruth17
VicTruth17 Jun. 4 at 1:12 PM
$ATHE 202 results loading on Doctor Stamler windows 98 😁😁😁😁 What’s up doc? Take us to AA with safety data :)
2 · Reply
NinjaRai
NinjaRai Jun. 3 at 8:37 AM
$ATHE $HBIO $LRHC
1 · Reply
SpartanVI
SpartanVI Jun. 3 at 8:36 AM
$LRHC adding some here could go like $ATHE $HBIO Oversold penny nice earnings last week
1 · Reply
theaussiebloke
theaussiebloke Jun. 2 at 6:37 PM
$ATHE Nice movement on bugger all volume, looks like it wants to test previous monthly highs of 4.64, $5+ will be new resistance once 202 results drop, than alot of news to come there after.
0 · Reply
VicTruth17
VicTruth17 Jun. 2 at 1:39 PM
$ATHE $CING let the accumulation begin for the incoming take off 🥰
1 · Reply